vs
Amphastar Pharmaceuticals, Inc.（AMPH）とEmpire State Realty Trust, Inc.（ESRT）の財務データ比較。上の社名をクリックして会社を切り替えられます
Empire State Realty Trust, Inc.の直近四半期売上が大きい（$190.3M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.0倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 1.6%、差は11.8%）。Empire State Realty Trust, Inc.の前年同期比売上増加率が高い（5.7% vs -1.8%）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 0.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
エンパイア・ステート・リアルティ・トラストは、ニューヨーク都市圏を中心にオフィス、小売店舗、住宅などの優良不動産を所有・運用する不動産投資信託で、象徴的なエンパイアステートビルもポートフォリオに含みます。持続可能な運用を通じ長期的な資産価値の向上を目指しています。
AMPH vs ESRT — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $190.3M |
| 純利益 | $24.4M | $3.0M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 15.5% |
| 純利益率 | 13.3% | 1.6% |
| 売上前年比 | -1.8% | 5.7% |
| 純利益前年比 | -35.7% | -73.7% |
| EPS（希薄化後） | $0.51 | $0.20 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $190.3M | ||
| Q4 25 | $183.1M | $199.2M | ||
| Q3 25 | $191.8M | $197.7M | ||
| Q2 25 | $174.4M | $191.3M | ||
| Q1 25 | $170.5M | $180.1M | ||
| Q4 24 | $186.5M | $197.6M | ||
| Q3 24 | $191.2M | $199.6M | ||
| Q2 24 | $182.4M | $189.5M |
| Q1 26 | — | $3.0M | ||
| Q4 25 | $24.4M | $32.2M | ||
| Q3 25 | $17.4M | $13.6M | ||
| Q2 25 | $31.0M | $11.4M | ||
| Q1 25 | $25.3M | $15.8M | ||
| Q4 24 | $38.0M | $18.8M | ||
| Q3 24 | $40.4M | $22.8M | ||
| Q2 24 | $37.9M | $28.6M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 15.5% | ||
| Q4 25 | 19.4% | 17.8% | ||
| Q3 25 | 13.2% | 19.9% | ||
| Q2 25 | 24.2% | 18.4% | ||
| Q1 25 | 21.9% | 14.3% | ||
| Q4 24 | 24.2% | 21.7% | ||
| Q3 24 | 29.8% | 22.7% | ||
| Q2 24 | 30.3% | 20.8% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 13.3% | 16.1% | ||
| Q3 25 | 9.0% | 6.9% | ||
| Q2 25 | 17.8% | 6.0% | ||
| Q1 25 | 14.8% | 8.8% | ||
| Q4 24 | 20.4% | 9.5% | ||
| Q3 24 | 21.1% | 11.4% | ||
| Q2 24 | 20.8% | 15.1% |
| Q1 26 | — | $0.20 | ||
| Q4 25 | $0.51 | $0.11 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $0.04 | ||
| Q1 25 | $0.51 | $0.05 | ||
| Q4 24 | $0.74 | $0.07 | ||
| Q3 24 | $0.78 | $0.08 | ||
| Q2 24 | $0.73 | $0.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $68.8M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $1.8B |
| 総資産 | $1.6B | $4.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $68.8M | ||
| Q4 25 | $282.8M | $132.7M | ||
| Q3 25 | $276.2M | $154.1M | ||
| Q2 25 | $231.8M | $94.6M | ||
| Q1 25 | $236.9M | $187.8M | ||
| Q4 24 | $221.6M | $385.5M | ||
| Q3 24 | $250.5M | $421.9M | ||
| Q2 24 | $217.8M | $535.5M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.8B | ||
| Q4 25 | $788.8M | $1.1B | ||
| Q3 25 | $776.7M | $1.0B | ||
| Q2 25 | $757.5M | $1.0B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $1.0B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $1.6B | $4.5B | ||
| Q3 25 | $1.7B | $4.1B | ||
| Q2 25 | $1.6B | $4.1B | ||
| Q1 25 | $1.6B | $4.1B | ||
| Q4 24 | $1.6B | $4.5B | ||
| Q3 24 | $1.5B | $4.4B | ||
| Q2 24 | $1.5B | $4.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | 10.0% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $249.1M | ||
| Q3 25 | $52.6M | $105.3M | ||
| Q2 25 | $35.6M | $26.7M | ||
| Q1 25 | $35.1M | $83.1M | ||
| Q4 24 | $29.0M | $260.9M | ||
| Q3 24 | $60.0M | $102.8M | ||
| Q2 24 | $69.1M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $50.6M | ||
| Q3 25 | $47.2M | $72.8M | ||
| Q2 25 | $25.0M | $-55.1M | ||
| Q1 25 | $24.4M | $41.1M | ||
| Q4 24 | $16.6M | $88.0M | ||
| Q3 24 | $46.2M | $-65.1M | ||
| Q2 24 | $63.1M | $19.5M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 25.4% | ||
| Q3 25 | 24.6% | 36.8% | ||
| Q2 25 | 14.3% | -28.8% | ||
| Q1 25 | 14.3% | 22.8% | ||
| Q4 24 | 8.9% | 44.5% | ||
| Q3 24 | 24.1% | -32.6% | ||
| Q2 24 | 34.6% | 10.3% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | 4.5% | 99.6% | ||
| Q3 25 | 2.8% | 16.5% | ||
| Q2 25 | 6.1% | 42.8% | ||
| Q1 25 | 6.3% | 23.4% | ||
| Q4 24 | 6.7% | 87.5% | ||
| Q3 24 | 7.2% | 84.1% | ||
| Q2 24 | 3.3% | 9.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 7.74× | ||
| Q3 25 | 3.03× | 7.72× | ||
| Q2 25 | 1.15× | 2.35× | ||
| Q1 25 | 1.39× | 5.27× | ||
| Q4 24 | 0.76× | 13.88× | ||
| Q3 24 | 1.48× | 4.51× | ||
| Q2 24 | 1.82× | 1.30× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ESRT
| Rental revenue (1) | $166.1M | 87% |
| Observatory revenue | $18.5M | 10% |
| Other revenue and fees | $4.1M | 2% |
| Lease termination fees | $1.4M | 1% |
| Third-party management and other fees | $277.0K | 0% |
